| Literature DB >> 29735888 |
Yanxue Cai1, Keren Kang2, Qianru Li3,4, Yu Wang5, Xiaowei He6.
Abstract
A reliable lateral flow immunoassay (LFIA) based on a facile one-step synthesis of single microspheres in combining with immunochromatography technique was developed to establish a new point-of-care test (POCT) for the rapid and early detection of cardiac troponin I (cTnI), a kind of cardiac specific biomarker for acute myocardial infarction (AMI). The double layered microspheres with clear core-shell structures were produced using soap-free emulsion polymerization method with inexpensive compounds (styrene and acrylic acid). The synthetic process was simple, rapid and easy to control due to one-step synthesis without any complicated procedures. The microspheres are nanostructure with high surface area, which have numerous carboxyl groups on the out layer, resulting in high-efficiency coupling between the carrier and antibody via amide bond. Meanwhile, the red fluorescent dye, Nile-red (NR), was wrapped inside the microspheres to improve its stability, as well to reduce the background noise, because of its higher emission wavelength than interference from real plasma samples. The core-shell structures provided different functional areas to separate antibody and dyes, so the immunoassay has highly sensitive, wide working curves in the range of 0⁻40 ng/mL, low limits of detection (LOD) at 0.016 ng/mL, and limits of quantification (LOQ) at 0.087 ng/mL with coefficient of variations (CV) of 10%. This strategy suggested an outstanding platform for LFIA, with good reproducibility and stability to straightforwardly analyze the plasma samples without washing steps, thereby reducing the operating procedures for non-professionals and promoting detection efficiency. The whole detection process can be completed in less than 15 min. This novel immunoassay offers a reliable and favorable analytical result by detecting the real samples, indicating that it holds great potential as a new alternative for biomolecule detection in complex samples, for the early detection of cardiac specific biomarkers.Entities:
Keywords: cardiac troponin I; clinical application; core-shell microspheres; lateral flow immunoassay; point-of-care tests
Mesh:
Substances:
Year: 2018 PMID: 29735888 PMCID: PMC6099710 DOI: 10.3390/molecules23051102
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The schematic representation of (I) The synthesis of fluorescent immune-microspheres; (II) Immunoassay mechanism lateral flow test strip and (III) Scanning & analysis process.
Figure 2(a) The spectrum and photo of microspheres with different solvents; (b) The fluorescence intensity at different concentration of NR with the DCM-water as solvent.
Figure 3The TEM images of (a) blank microspheres and (b) fluorescent microspheres; (c) The particle size and (d) ζ-potential of blank and fluorescent microspheres (FM); (e) The FTIR spectrum of blank microspheres (grey line), NR (pink line) and fluorescent microspheres (red line).
Figure 4(a) The fluorescence signal intensity at different sites on the NC membrane at cTnI concentration from 0 to 80 ng/mL; (b) The photo of detection strips under UV-light; (c) The ratio of HT/HC and the corresponding coefficient of variations; (d) The standard curve of cTnI test.
The comparison of performance for cTnI from reported literatures and current work.
| Method | LOD | Stability | Time |
|---|---|---|---|
| Cationic isotachophoresis [ | 46 ng/mL | - | ~10 min |
| Wavelength modulation SPR biosensor [ | 37.5 ng/mL | - | ~70 min |
| Fluorogenic noncompetitive immunoassay [ | 6.7 ng/mL | - | ~19 min |
| Capillary tube indicators [ | 0.1 ng/mL | - | ~20 min |
| Electrochemical immunosensor [ | 0.05 ng/mL | 30 days | ~15 min |
| Red florescent microspheres immunoassay (This work) | 0.016 ng/mL | 90 days | ~15 min |
| Pt NPs modified hybrid film immunosensor [ | 1 pg/mL | 1 month | ~20 min |
Figure 5The cTnI concentration of LOQ at 10% CV and 20% CV from 0 to 0.30 ng/mL.
The comparison of limit of quantification (LOQ) for cTnI from reported literatures and current work.
| Method | LOQ (ng/mL) | |
|---|---|---|
| CV < 10% | CV < 20% | |
| Immunoassay sandwich fluorescence ( bioMerieux VIDAS) [ | 0.11 | - |
| Enzyme-linked immunosorbent assay (i-STAT) [ | 0.10 | 0.07 |
| Microfluidic immunochip assay [ | - | 0.042 |
| Homogeneous sandwich immunoassay [ | - | 0.038 |
| Red florescent microspheres immunoassay (This work) | 0.087 | 0.032 |
Results of reproducibility analysis by intra-assay and inter-assay precision.
| cTnI (ng/mL) | Intra-Assay Precision ( | Inter-Assay Precision ( | ||
|---|---|---|---|---|
| Mean ± SD (ng/mL) | CV (%) | Mean ± SD (ng/mL) | CV (%) | |
| 2.40 | 2.32 ± 0.09 | 3.86 | 2.54 ± 0.12 | 4.69 |
| 19.83 | 19.28 ± 0.51 | 2.67 | 20.40 ± 0.87 | 4.26 |
| 40.42 | 41.58 ± 2.57 | 6.18 | 39.47 ± 2.80 | 7.10 |
The specificity study of the developed method with different interferons.
| Interfering Substance | cTnI (1.3 ng/mL) | cTnI (2.85 ng/mL) | ||
|---|---|---|---|---|
| Value | RD (%) | Value | RD (%) | |
| Control | 1.31 ± 0.01 | 0.77 | 2.93 ± 0.08 | 2.81 |
| Bilirubin (2 ng/mL) | 1.24 ± 0.02 | −4.62 | 2.69 ± 0.09 | −5.61 |
| Cholesterol (15 ng/mL) | 1.31 ± 0.04 | 0.77 | 2.64 ± 0.01 | −7.37 |
| Sodium aside (6 ng/mL) | 1.27 ± 0.01 | −2.31 | 2.76 ± 0.05 | −3.16 |
| Hemoglobin (10 ng/mL) | 1.23 ± 0.05 | −5.38 | 2.75 ± 0.07 | −3.51 |
Note: RD = (Value − Standard value)/Standard value.
Figure 6The results clinical test of cTnI (a) and the average difference (b).